

**Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, Rapid Test, Western Blotting, ELISPOT), Specimen (Blood, Saliva), Application (Infectious Diseases, Oncology), End User (Hospitals & Clinics) - Global Forecasts to 2027**

Market Report | 2022-08-15 | 417 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global immunoassay market is valued at an estimated USD 40.2 billion in 2022 and is projected to reach USD 49.6 billion by 2027, at a CAGR of 4.3% during the forecast period. Market growth is driven by factors such as the increasing incidence of chronic and infectious diseases, advancements in systems and technologies, growth in the biotechnology and biopharmaceutical industries, supportive government policies, increasing adoption of immunoassay-based POC testing and rapid testing, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing.

"The reagents & kits to register the largest share of the immunoassay market, by product"

The global immunoassay market is segmented into reagents & kits and analyzers based on product. Market growth is largely driven by the large consumption of reagents & kits for various procedures along with the rising volume of immunoassay-based tests performed worldwide.

"Rapid Tests segment to grow at a considerable rate among technology during the forecast period"

The immunoassay market is segmented into ELISA, rapid tests, ELISpot, western blotting, radioimmunoassays, and other technologies. Rapid tests are used to test donated blood for the detection of HIV, HCV, HBV, and HCG antibodies. Rapid tests are preferred as a preferred method in POC diagnosis, particularly in emergency and primary care settings.

"The blood segment accounted to grow at the fastest rate, by specimen, in 2021"

Based on specimens, the immunoassay market is segmented into blood, saliva, urine, and other specimens. In 2021, blood specimens is anticipated to witness growth at the highest rate owing to increasing incidence of chronic and infectious diseases and rise in the rate of blood donations.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

"Infectious diseases segment to register the highest growth rate among applications during the forecast period"

The global immunoassay market is segmented into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, and other applications. The application segment of infectious diseases is anticipated to grow that the highest CAGR during the forecast period, owing to the rise in the number of products being launched for its diagnosis.

"Among the end users, the hospitals & clinics segment anticipated to grow at a significant rate during the forecast period"

The rise in the prevalence of chronic and infectious diseases has led to significant growth of the hospitals & clinics end user segment. The segment is also consider to register highest growth rate during the forecast period.

"The Asia Pacific market is expected to grow at the highest CAGR during the forecast period"

The global immunoassay market is segmented into five regions - North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America. The Asia Pacific region is expected to witness the highest growth in the immunoassay market during the forecast period. The high growth in this region can primarily be attributed to the increasing geriatric population, and high disease burden of chronic disorders along with developing healthcare infrastructure in Asian countries such as India and China.

The primary interviews conducted for this report can be categorized as follows:

-□By Company Type: Tier 1 - 28%, Tier 2 - 41%, and Tier 3 - 31%

-□By Designation: C-level - 30%, D-level - 34%, and Others - 36%

-□By Region: North America - 38%, Europe - 27%, Asia Pacific - 18%, Middle East & Africa - 11%, and Latin America - 6%

Lists of Companies Profiled in the Report:

-□Abbott Laboratories (US)

-□F. Hoffmann-La Roche (Switzerland)

-□Siemens Healthineers (Germany)

-□Thermo Fisher Scientific (US)

-□Danaher Corporation (US)

-□PerkinElmer (US)

-□Becton, Dickinson and Company (US)

-□DiaSorin S.p.A. (Italy)

-□Bio- Rad Laboratories (US)

-□Quidel Corporation (US)

-□Ortho Clinical Diagnostics Holdings (US)

-□bioMerieux (France)

-□QIAGEN (Netherlands)

-□Sysmex Corporation (Japan)

-□Agilent Technologies (US)

-□Mindray Medical International Company (China)

-□Merck KGaA (Germany)

-□Meridian Bioscience (US)

-□Bio-Techne (US)

-□Cellabs (Australia)

-□Abnova Corporation (Taiwan)

-□J. Mitra & Co. Pvt. Ltd. (India)

-□Tosoh Corporation (Japan)

-□Cell Sciences (US)

-□Enzo Biochem (US)

-□Creative Diagnostics (US)

-□Boster Biological Technology (US)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Elabscience (US)
- WAK-Chemie Medical (Germany)
- Sera Care (US)
- Epitope Diagnostics (US)
- Kamiya Biomedical Company (US)
- Gyros Protein Technologies (Sweden)
- Trivitron Healthcare (India)
- InBios International (US).

#### Research Coverage:

This report provides a detailed picture of the global immunoassay market. It aims at estimating the size and future growth potential of the market across different segments, such as product, technology, specimen, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

#### Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunoassay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.

#### Table of Contents:

1	INTRODUCTION	44
1.1	STUDY OBJECTIVES	44
1.2	MARKET DEFINITION	44
1.2.1	INCLUSIONS & EXCLUSIONS	44
1.3	MARKET SCOPE	45
FIGURE 1	IMMUNOASSAY MARKET	45
1.3.1	YEARS CONSIDERED	46
1.4	CURRENCY CONSIDERED	46
1.5	STAKEHOLDERS	46
1.6	SUMMARY OF CHANGES	47
2	RESEARCH METHODOLOGY	48
2.1	RESEARCH DATA	48
FIGURE 2	RESEARCH DESIGN	48
2.1.1	SECONDARY DATA	49
2.1.1.1	Secondary sources	50
2.1.2	PRIMARY DATA	50
2.1.2.1	Key data from primary sources	51
2.1.2.2	Key industry insights	52
FIGURE 3	BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS	53
FIGURE 4	BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	53
2.2	MARKET SIZE ESTIMATION	53
2.2.1	BOTTOM-UP APPROACH	54
FIGURE 5	MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH	54
FIGURE 6	MARKET SIZE ESTIMATION: TOP-DOWN APPROACH	55

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 7	CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS	55
2.3	MARKET BREAKDOWN AND DATA TRIANGULATION	56
FIGURE 8	DATA TRIANGULATION METHODOLOGY	56
2.4	MARKET SHARE ANALYSIS	57
2.5	STUDY ASSUMPTIONS	57
2.6	RISK ASSESSMENT	57
TABLE 1	RISK ASSESSMENT: IMMUNOASSAY MARKET	57
2.7	LIMITATIONS	58
2.7.1	METHODOLOGY-RELATED LIMITATIONS	58
2.7.2	SCOPE-RELATED LIMITATIONS	58
2.8	GROWTH RATE ASSUMPTIONS	58
3	EXECUTIVE SUMMARY	59
FIGURE 9	IMMUNOASSAY MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION)	59
FIGURE 10	IMMUNOASSAY MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD BILLION)	60
FIGURE 11	IMMUNOASSAY MARKET, BY SPECIMEN, 2022 VS. 2027 (USD BILLION)	61
FIGURE 12	IMMUNOASSAY MARKET, BY APPLICATION, 2022 VS. 2027 (USD BILLION)	62
FIGURE 13	IMMUNOASSAY MARKET, BY END USER, 2022 VS. 2027 (USD BILLION)	63
FIGURE 14	GEOGRAPHICAL SNAPSHOT OF IMMUNOASSAY MARKET	64
4	PREMIUM INSIGHTS	65
4.1	IMMUNOASSAY MARKET OVERVIEW	65
FIGURE 15	RIISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS-KEY DRIVERS OF MARKET GROWTH	65
4.2	NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT & COUNTRY (2021)	66
FIGURE 16	REAGENTS & KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021	66
4.3	IMMUNOASSAY MARKET: GEOGRAPHICAL SNAPSHOT	67
FIGURE 17	CHINA & INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD	67
4.4	IMMUNOASSAY MARKET: GEOGRAPHIC MIX	68
FIGURE 18	APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD	68
4.5	IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS	69
FIGURE 19	DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD	69
5	MARKET OVERVIEW	70
5.1	INTRODUCTION	70
5.2	MARKET DYNAMICS	70
FIGURE 20	IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	70
5.2.1	DRIVERS	71
5.2.1.1	Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis	71
FIGURE 21	INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)	71
TABLE 2	GLOBAL INCIDENCE OF INFECTIOUS DISEASES	72
5.2.1.1.1	Increasing use of immunoassays in oncology	72
TABLE 3	GLOBAL INCIDENCE OF TOP CANCERS IN MEN, 2020	73
TABLE 4	GLOBAL INCIDENCE OF TOP CANCERS IN WOMEN, 2020	73
5.2.1.1.2	Immunoassays for COVID-19 and other viral diagnostics	74
5.2.1.1.3	Immunoassays in drug detection and other diagnostic applications	74
TABLE 5	DETECTION OF DRUGS BY URINE TESTING	75
5.2.1.1.4	Growing geriatric population	75
FIGURE 22	GLOBAL AGING POPULATION, BY REGION, 2019 VS. 2050 (MILLION)	75
5.2.1.2	Advancements in systems and technologies	76
5.2.1.3	Growth in biotechnology and biopharmaceutical industries	77

5.2.1.4	Increasing adoption of immunoassay-based POC testing and rapid testing	77
TABLE 6 RECENT WAIVERS OF MARKET PRODUCTS		
5.2.1.5	Supportive government policies	79
5.2.1.6	Increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing	79
5.2.2	RESTRAINTS	80
5.2.2.1	Stringent requirements for approval of immunoassay instruments and consumables	80
5.2.2.2	Technical hurdles of immunoassay kits	80
5.2.3	OPPORTUNITIES	81
5.2.3.1	Growth opportunities in emerging economies	81
5.2.3.2	Importance of companion diagnostics	82
TABLE 7 COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED		
5.2.3.3	Development of condition-specific biomarkers and tests	83
TABLE 8 NEW TESTS LAUNCHED BY KEY PLAYERS		
5.2.3.4	Integration of microfluidics in immunoassays	84
TABLE 9 LAB-ON-A-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY PLAYERS		
5.2.3.5	Improving immunoassay diagnostic technologies	85
5.2.4	CHALLENGES	85
5.2.4.1	Design challenges, complexities, and quality of antibodies	85
5.2.4.2	Dearth of skilled professionals	86
5.2.4.3	Unfavorable reimbursement scenario	86
5.2.4.4	Financial hurdles faced by physicians	86
5.3	REGULATORY OVERVIEW	87
5.3.1	US	87
TABLE 10 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS		
FIGURE 23 US: REGULATORY PROCESS FOR IVD DEVICES		
5.3.2	CANADA	89
FIGURE 24 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA		
5.3.3	EUROPE	89
TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES		
5.3.4	JAPAN	90
5.3.4.1	Japan: Regulatory process for IVD devices	90
TABLE 12 JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN		
TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS		
5.3.5	CHINA	91
TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS		
5.3.6	INDIA	92
5.3.6.1	India: Regulatory process for IVD devices	92
5.3.7	INDONESIA	93
TABLE 15 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES		
5.3.8	RUSSIA	93
TABLE 16 RUSSIA: CLASSIFICATION OF IVD DEVICES		
5.3.9	SAUDI ARABIA	94
TABLE 17 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS		
5.3.10	MEXICO	94
5.3.10.1	Mexico: Regulatory process for IVD devices	95
TABLE 18 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS		
5.3.11	BRAZIL	96

5.3.11.1	Brazil: Regulatory process for IVD devices	96
5.3.12	SOUTH KOREA	96
TABLE 19	SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS	96
5.3.13	MIDDLE EAST	97
5.3.14	AFRICA	97
5.4	TECHNOLOGY ANALYSIS	97
TABLE 20	CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES	97
TABLE 21	RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET	98
5.5	TRADE ANALYSIS	98
5.5.1	TRADE ANALYSIS FOR IMMUNOASSAYS	98
TABLE 22	IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2017-2021 (USD MILLION)	99
TABLE 23	EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2016-2020 (USD MILLION)	99
5.6	PATENT ANALYSIS	100
5.7	VALUE CHAIN ANALYSIS	101
FIGURE 25	VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES	101
5.8	SUPPLY CHAIN ANALYSIS	102
FIGURE 26	DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES	102
5.9	ECOSYSTEM ANALYSIS OF IMMUNOASSAY MARKET	103
FIGURE 27	ECOSYSTEM ANALYSIS OF IMMUNOASSAY MARKET	103
5.9.1	ROLE IN ECOSYSTEM	103
5.9.2	KEY PLAYERS OPERATING IN IMMUNOASSAY MARKET	104
5.10	PORTER'S FIVE FORCES ANALYSIS	105
TABLE 24	HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS	105
5.10.1	DEGREE OF COMPETITION	105
5.10.2	BARGAINING POWER OF SUPPLIERS	105
5.10.3	BARGAINING POWER OF BUYERS	105
5.10.4	THREAT FROM SUBSTITUTES	105
5.10.5	THREAT FROM NEW ENTRANTS	106
5.11	KEY CONFERENCES & EVENTS IN 2022	106
TABLE 25	LIST OF CONFERENCES & EVENTS	106
5.12	PRICING ANALYSIS	107
TABLE 26	IMMUNOASSAY: PRICE RANGE FOR IMMUNOASSAY PRODUCTS	107
5.13	KEY STAKEHOLDERS & BUYING CRITERIA	108
5.13.1	KEY STAKEHOLDERS IN BUYING PROCESS	108
FIGURE 28	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER	108
TABLE 27	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS	108
5.13.2	BUYING CRITERIA	109
FIGURE 29	KEY BUYING CRITERIA FOR TOP END USERS	109
TABLE 28	KEY BUYING CRITERIA, BY END USER	109
5.14	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	110
5.15	SCENARIO-BASED MARKET ASSESSMENT	111
5.15.1	IMMUNOASSAY MARKET FORECAST	111
FIGURE 30	PESSIMISTIC SCENARIO	111
FIGURE 31	OPTIMISTIC SCENARIO	111
FIGURE 32	REALISTIC SCENARIO	112
6	IMMUNOASSAY MARKET, BY PRODUCT	113
6.1	INTRODUCTION	114

TABLE 29	IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	114
6.2	REAGENTS & KITS	114
TABLE 30	IMMUNOASSAY REAGENTS & KITS AVAILABLE IN MARKET	115
TABLE 31	IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020-2027 (USD MILLION)	116
TABLE 32	IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION)	116
6.2.1	ELISA REAGENTS & KITS	117
6.2.1.1	Wide usage in basic research and high-throughput screening	117
TABLE 33	ELISA REAGENTS & KITS MARKET, BY REGION, 2020-2027 (USD MILLION)	118
6.2.2	RAPID TEST REAGENTS & KITS	118
6.2.2.1	High demand for rapid test reagents & kits in remote areas to drive growth	118
TABLE 34	RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2020-2027 (USD MILLION)	119
6.2.3	ELISPOT REAGENTS & KITS	119
6.2.3.1	High sensitivity, functionality, and adaptability of ELISpot technology to drive demand	119
TABLE 35	ELISPOT REAGENTS & KITS MARKET, BY REGION, 2020-2027 (USD MILLION)	120
6.2.4	WESTERN BLOT REAGENTS & KITS	120
6.2.4.1	Gold standard for result confirmation promotes Western blotting reagents & kits	120
TABLE 36	WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2020-2027 (USD MILLION)	121
6.2.5	OTHER REAGENTS & KITS	121
TABLE 37	OTHER IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020-2027 (USD MILLION)	122
6.3	ANALYZERS	122
TABLE 38	IMMUNOASSAY ANALYZERS AVAILABLE IN MARKET	123
TABLE 39	IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020-2027 (USD MILLION)	124
6.3.1	IMMUNOASSAY ANALYZERS MARKET, BY TYPE	124
TABLE 40	IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION)	125
6.3.1.1	Open-ended systems	125
6.3.1.1.1	Flexibility and wide availability make open-ended systems popular among users	125
TABLE 41	OPEN-ENDED SYSTEMS MARKET, BY REGION, 2020-2027 (USD MILLION)	125
6.3.1.2	Closed-ended systems	126
6.3.1.2.1	High precision and automation are key features of closed-ended systems	126
TABLE 42	CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2020-2027 (USD MILLION)	126
6.3.2	IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE	126
TABLE 43	IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION)	126
6.3.2.1	Rental purchase	127
6.3.2.1.1	Convenience and lack of liability for end users drive preference for device rental	127
TABLE 44	RENTAL PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020-2027 (USD MILLION)	127
6.3.2.2	Outright purchase	128
6.3.2.2.1	Outright purchase is favored by government organizations, big companies, and CROs	128
TABLE 45	OUTRIGHT PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020-2027 (USD MILLION)	128
7	IMMUNOASSAY MARKET, BY TECHNOLOGY	129
7.1	INTRODUCTION	130
TABLE 46	IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	130
7.2	ELISA	130
TABLE 47	KEY ELISA SYSTEMS AVAILABLE IN MARKET	131
TABLE 48	IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2020-2027 (USD MILLION)	132
7.2.1	ELISA MARKET, BY GENERATION	132
TABLE 49	IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION)	132
7.2.1.1	Third-generation & above	133

7.2.1.1.1	Third- & fourth-gen ELISA show high specificity and accuracy	133
TABLE 50	THIRD-GENERATION & ABOVE ELISA MARKET, BY REGION, 2020-2027 (USD MILLION)	133
7.2.1.2	Second-generation & below	134
7.2.1.2.1	Cost-effectiveness of first- and second-generation tests supports their use	134
TABLE 51	SECOND-GENERATION & BELOW ELISA MARKET, BY REGION, 2020-2027 (USD MILLION)	134
7.2.2	ELISA MARKET, BY TYPE	135
TABLE 52	IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION)	135
7.2.2.1	CLIA	135
7.2.2.1.1	CLIA holds largest share of ELISA market, by type	135
TABLE 53	CLIA MARKET, BY REGION, 2020-2027 (USD MILLION)	136
7.2.2.2	IFA	136
7.2.2.2.1	IFA is used to diagnose antibodies against infectious pathogens	136
TABLE 54	IFA MARKET, BY REGION, 2020-2027 (USD MILLION)	137
7.2.2.3	Colorimetric immunoassays	137
7.2.2.3.1	Introduction of advanced techniques will support market growth	137
TABLE 55	COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020-2027 (USD MILLION)	138
7.3	RAPID TESTS	138
7.3.1	WIDE USE OF RAPID TESTS IN EMERGING COUNTRIES OR AREAS WITH LIMITED TECHNOLOGY ACCESS TO DRIVE GROWTH	138
TABLE 56	KEY RAPID TESTS AVAILABLE IN MARKET	138
TABLE 57	IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2020-2027 (USD MILLION)	139
7.4	WESTERN BLOTTING	140
7.4.1	WIDE USE IN RESULT CONFIRMATION AND ANTIBODY DETECTION RESPONSIBLE FOR MARKET GROWTH	140
TABLE 58	WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET	140
TABLE 59	IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2020-2027 (USD MILLION)	140
7.5	RADIOIMMUNOASSAYS	141
7.5.1	HIGH USAGE OF RIA FOR DIAGNOSIS AND DRUG TESTING TO DRIVE GROWTH	141
TABLE 60	IMMUNOASSAY MARKET FOR RADIOIMMUNOASSAYS, BY REGION, 2020-2027 (USD MILLION)	141
7.6	ELISPOT	141
7.6.1	HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY OF ELISPOT DRIVE ADOPTION OF ASSAYS	141
TABLE 61	IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2020-2027 (USD MILLION)	142
7.7	OTHER TECHNOLOGIES	142
TABLE 62	IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020-2027 (USD MILLION)	143
8	IMMUNOASSAY MARKET, BY SPECIMEN	144
8.1	INTRODUCTION	145
TABLE 63	IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION)	145
8.2	BLOOD	145
8.2.1	HIGH RELIABILITY OF BLOOD TESTS WILL ENSURE STABLE MARKET GROWTH	145
TABLE 64	IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION, 2020-2027 (USD MILLION)	146
8.3	SALIVA	147
8.3.1	CONVENIENCE AND APPLICATIONS OF SALIVA TESTS TO SUPPORT MARKET GROWTH	147
TABLE 65	IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION, 2020-2027 (USD MILLION)	147
8.4	URINE	148
8.4.1	USE IN LAW ENFORCEMENT AND DRUG TESTING APPLICATIONS DRIVES DEMAND FOR URINE-BASED TESTS	148
TABLE 66	IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION, 2020-2027 (USD MILLION)	148
8.5	OTHER SPECIMENS	149
TABLE 67	IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2020-2027 (USD MILLION)	149
9	IMMUNOASSAY MARKET, BY APPLICATION	150

## 9.1 INTRODUCTION 151

TABLE 68 IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 151

## 9.2 INFECTIOUS DISEASES 152

### 9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 152

TABLE 69 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020-2027 (USD MILLION) 152

## 9.3 ENDOCRINOLOGY 153

### 9.3.1 RISING GLOBAL DIABETES INCIDENCE WILL DRIVE DEMAND FOR IMMUNOASSAYS 153

TABLE 70 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY APPLICATIONS, BY REGION, 2020-2027 (USD MILLION) 153

## 9.4 CARDIOLOGY 154

### 9.4.1 HIGH BURDEN OF CVD TO SUPPORT MARKET GROWTH 154

TABLE 71 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR CARDIOLOGY APPLICATIONS 154

TABLE 72 IMMUNOASSAY MARKET FOR CARDIOLOGY APPLICATIONS, BY REGION, 2020-2027 (USD MILLION) 155

## 9.5 AUTOIMMUNE DISORDERS 155

### 9.5.1 RISING ECONOMIC BURDEN OF AUTOIMMUNE DISORDER TREATMENT-A KEY FACTOR DRIVING MARKET GROWTH 155

TABLE 73 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2020-2027 (USD MILLION) 156

## 9.6 ALLERGY DIAGNOSTICS 156

### 9.6.1 GROWING PREVALENCE OF ALLERGIES TO INCREASE DEMAND FOR IMMUNOASSAYS 156

TABLE 74 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2020-2027 (USD MILLION) 157

## 9.7 ONCOLOGY 157

### 9.7.1 RISING BURDEN OF CANCER-A POSITIVE INDICATOR OF MARKET GROWTH 157

TABLE 75 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 158

TABLE 76 IMMUNOASSAY MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2020-2027 (USD MILLION) 159

## 9.8 BONE & MINERAL DISORDERS 159

### 9.8.1 HIGH DISORDER PREVALENCE INDICATES STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS 159

TABLE 77 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR BONE & MINERAL DISORDER DIAGNOSIS 160

TABLE 78 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2020-2027 (USD MILLION) 160

## 9.9 TOXICOLOGY 160

### 9.9.1 DRUG ABUSE AND ILICIT DRUG CONSUMPTION ENSURE DEMAND FOR IMMUNOASSAYS IN TOXICOLOGY 160

TABLE 79 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUG MONITORING 161

TABLE 80 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUGS-OF-ABUSE/TOXICOLOGY ASSAYS 161

TABLE 81 IMMUNOASSAY MARKET FOR TOXICOLOGY APPLICATIONS, BY REGION, 2020-2027 (USD MILLION) 162

## 9.10 BLOOD SCREENING 162

### 9.10.1 RISING BLOOD DONATION VOLUMES FAVOR DEMAND FOR IMMUNOASSAYS 162

TABLE 82 IMMUNOASSAY MARKET FOR BLOOD SCREENING APPLICATIONS, BY REGION, 2020-2027 (USD MILLION) 163

## 9.11 NEWBORN SCREENING 163

### 9.11.1 IMMUNOASSAYS USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL-A MAJOR DRIVING FACTOR 163

TABLE 83 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR NEWBORN SCREENING 164

TABLE 84 IMMUNOASSAY MARKET FOR NEWBORN SCREENING APPLICATIONS, BY REGION, 2020-2027 (USD MILLION) 165

## 9.12 OTHER APPLICATIONS 165

TABLE 85 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION) 166

## 10 IMMUNOASSAY MARKET, BY END USER 167

### 10.1 INTRODUCTION 168

TABLE 86 IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION) 168

### 10.2 HOSPITALS & CLINICS 168

#### 10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES DRIVE MARKET GROWTH 168

TABLE 87 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020-2027 (USD MILLION) 169

### 10.3 CLINICAL LABORATORIES 170

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.3.1	RISING CLINICAL TEST VOLUMES AND REQUIREMENTS SUPPORT USE OF IMMUNOASSAYS IN CLINICAL LABS	170
TABLE 88	IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020-2027 (USD MILLION)	171
10.4	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS	171
10.4.1	GROWING DRUG DISCOVERY AND CLINICAL STUDY ACTIVITY DRIVES DEMAND FOR IMMUNOASSAYS IN PHARMA-BIOTECH INDUSTRY	171
TABLE 89	IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2020-2027 (USD MILLION)	172
10.5	HOME CARE SETTINGS	172
10.5.1	RELIANCE ON AT-HOME TESTS AND POC DIAGNOSTICS BOOSTS MARKET GROWTH	172
TABLE 90	IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2020-2027 (USD MILLION)	173
10.6	BLOOD BANKS	173
10.6.1	RISING DEMAND FOR BLOOD AND GROWING BLOOD DONATION VOLUMES DRIVE USE OF IMMUNOASSAYS FOR SCREENING	173
TABLE 91	IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2020-2027 (USD MILLION)	174
10.7	RESEARCH & ACADEMIC LABORATORIES	174
10.7.1	RISING NUMBER OF COLLEGES & UNIVERSITIES DRIVES MARKET GROWTH	174
TABLE 92	IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2020-2027 (USD MILLION)	175
11	IMMUNOASSAY MARKET, BY REGION	176
11.1	INTRODUCTION	177
TABLE 93	IMMUNOASSAY MARKET, BY REGION, 2020-2027 (USD MILLION)	177
11.2	NORTH AMERICA	178
FIGURE 33	NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT	179
TABLE 94	NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	180
TABLE 95	NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	180
TABLE 96	NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION)	181
TABLE 97	NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION)	181
TABLE 98	NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION)	182
TABLE 99	NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	182
TABLE 100	NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION)	183
TABLE 101	NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION)	183
TABLE 102	NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION)	184
TABLE 103	NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	184
TABLE 104	NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION)	185
11.2.1	US	185
11.2.1.1	US holds largest share in North American market	185
TABLE 105	US: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	186
TABLE 106	US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION)	187
TABLE 107	US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION)	187
TABLE 108	US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION)	188
TABLE 109	US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	188
TABLE 110	US: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION)	189
TABLE 111	US: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION)	189
TABLE 112	US: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION)	190
TABLE 113	US: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	190
TABLE 114	US: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION)	191
11.2.2	CANADA	191
11.2.2.1	Initiatives undertaken by government bodies to support growth of market in Canada	191

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 115	CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	192
TABLE 116	CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION)	193
TABLE 117	CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION)	193
TABLE 118	CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION)	194
TABLE 119	CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	194
TABLE 120	CANADA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION)	195
TABLE 121	CANADA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION)	195
TABLE 122	CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION)	196
TABLE 123	CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	196
TABLE 124	CANADA: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION)	197
11.3	EUROPE	197
TABLE 125	EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	198
TABLE 126	EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	199
TABLE 127	EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION)	199
TABLE 128	EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION)	200
TABLE 129	EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION)	200
TABLE 130	EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	201
TABLE 131	EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION)	201
TABLE 132	EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION)	202
TABLE 133	EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION)	202
TABLE 134	EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	203
TABLE 135	EUROPE: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION)	203
11.3.1	GERMANY	204
11.3.1.1	Germany holds largest share of EU immunoassay market	204
TABLE 136	GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	205
TABLE 137	GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION)	205
TABLE 138	GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION)	206
TABLE 139	GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION)	206
TABLE 140	GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	207
TABLE 141	GERMANY: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION)	207
TABLE 142	GERMANY: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION)	208
TABLE 143	GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION)	208
TABLE 144	GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	209
TABLE 145	GERMANY: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION)	209
11.3.2	ITALY	210
11.3.2.1	Growing geriatric population and increasing support for research to support market growth	210
TABLE 146	ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION)	210
TABLE 147	ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION)	211
TABLE 148	ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION)	211
TABLE 149	ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION)	212
TABLE 150	ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	212
TABLE 151	ITALY: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION)	213
TABLE 152	ITALY: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION)	213
TABLE 153	ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION)	214
TABLE 154	ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	214
TABLE 155	ITALY: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION)	215
11.3.3	FRANCE	215

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

11.3.3.1 Rising use of POC testing and favorable reimbursement policies make France a lucrative market 215

TABLE 156 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 216

TABLE 157 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION) 216

TABLE 158 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION) 217

TABLE 159 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION) 217

TABLE 160 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 218

TABLE 161 FRANCE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION) 218

TABLE 162 FRANCE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION) 219

TABLE 163 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION) 219

TABLE 164 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 220

TABLE 165 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION) 220

11.3.4 SPAIN 221

11.3.4.1 Increasing adoption of technologically advanced immunoassay systems makes Spain a relatively large market 221

TABLE 166 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 221

TABLE 167 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION) 222

TABLE 168 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION) 222

TABLE 169 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION) 223

TABLE 170 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 223

TABLE 171 SPAIN: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION) 224

TABLE 172 SPAIN: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION) 224

TABLE 173 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION) 225

TABLE 174 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 225

TABLE 175 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION) 226

11.3.5 UK 226

11.3.5.1 Government support for disease diagnostics and favorable investment scenario drive market in UK 226

TABLE 176 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 227

TABLE 177 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION) 228

TABLE 178 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION) 228

TABLE 179 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION) 229

TABLE 180 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 229

TABLE 181 UK: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION) 230

TABLE 182 UK: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION) 230

TABLE 183 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION) 231

TABLE 184 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 231

TABLE 185 UK: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION) 232

11.3.6 RUSSIA 232

11.3.6.1 Lack of reimbursement and delays in approval may hinder market growth 232

TABLE 186 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 233

TABLE 187 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION) 233

TABLE 188 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION) 234

TABLE 189 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION) 234

TABLE 190 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 235

TABLE 191 RUSSIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION) 235

TABLE 192 RUSSIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION) 236

TABLE 193 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION) 236

TABLE 194 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 237

TABLE 195 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION) 237

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

### 11.3.7 REST OF EUROPE 238

TABLE 196 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 238

TABLE 197 REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION) 239

TABLE 198 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION) 239

TABLE 199 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION) 240

TABLE 200 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 240

TABLE 201 REST OF EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION) 241

TABLE 202 REST OF EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION) 241

TABLE 203 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION) 242

TABLE 204 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 242

TABLE 205 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION) 243

### 11.4 ASIA PACIFIC 243

FIGURE 34 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT 244

TABLE 206 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 245

TABLE 207 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 245

TABLE 208 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION) 246

TABLE 209 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION) 246

TABLE 210 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION) 247

TABLE 211 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 247

TABLE 212 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION) 248

TABLE 213 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION) 248

TABLE 214 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION) 249

TABLE 215 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 249

TABLE 216 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION) 250

#### 11.4.1 JAPAN 250

11.4.1.1 Investments in healthcare technology and research to support growth in Japan 250

TABLE 217 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 251

TABLE 218 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION) 251

TABLE 219 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION) 252

TABLE 220 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION) 252

TABLE 221 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 253

TABLE 222 JAPAN: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION) 253

TABLE 223 JAPAN: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION) 254

TABLE 224 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION) 254

TABLE 225 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 255

TABLE 226 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION) 255

#### 11.4.2 CHINA 256

11.4.2.1 Opportunities for growth in China hampered by long product approval and registration processes 256

TABLE 227 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 257

TABLE 228 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION) 257

TABLE 229 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION) 258

TABLE 230 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION) 258

TABLE 231 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 259

TABLE 232 CHINA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION) 259

TABLE 233 CHINA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION) 260

TABLE 234 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION) 260

TABLE 235 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 261

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 236 CHINA: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION) 261

11.4.3 INDIA 262

11.4.3.1 Growing medical tourism and healthcare infrastructure will drive use of immunoassays in India 262

TABLE 237 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 263

TABLE 238 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020-2027 (USD MILLION) 263

TABLE 239 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020-2027 (USD MILLION) 264

TABLE 240 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020-2027 (USD MILLION) 264

TABLE 241 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 265

TABLE 242 INDIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020-2027 (USD MILLION) 265

TABLE 243 INDIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020-2027 (USD MILLION) 266

TABLE 244 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020-2027 (USD MILLION) 266

TABLE 245 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 267

TABLE 246 INDIA: IMMUNOASSAY MARKET, BY END USER, 2020-2027 (USD MILLION) 267

**Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, Rapid Test, Western Blotting, ELISPOT), Specimen (Blood, Saliva), Application (Infectious Diseases, Oncology), End User (Hospitals & Clinics) - Global Forecasts to 2027**

Market Report | 2022-08-15 | 417 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code\*

Country\*

Date

Signature